Michael David Garrison, Executive Vice President and President of Medical (TASE:PMCN) at Becton Dickinson & Co (NYSE:NYSE:BDX), sold 2,838 shares of the company's common stock on December 19, 2024. The shares were sold at an average price of $223.33, bringing the total transaction value to approximately $633,810. Following this sale, Garrison retains ownership of 6,141 shares in the company. The transaction was executed under a Rule 10b5-1 plan, which was adopted on August 2, 2024. According to InvestingPro, BDX maintains strong fundamentals with a "GOOD" Financial Health score and has raised its dividend for 54 consecutive years. For deeper insights into BDX's valuation and more exclusive ProTips, investors can access the comprehensive Pro Research Report, available with an InvestingPro subscription.
In other recent news, Becton Dickinson (BD), a global medical technology company, reported robust financial growth in its fourth quarter and full-year fiscal 2024 earnings call. Despite facing challenges in China and the Bioscience-Pharma sector, the company saw significant growth in its MedTech and Diagnostics segments. BD reported Q4 revenue growth of 7.4% and a full-year organic revenue increase of 5%. The company's adjusted diluted earnings per share (EPS) rose by 11.4%, reaching $13.14 for the full year.
In terms of future developments, BD anticipates revenue between $21.9 billion and $22.1 billion for FY '25, with adjusted diluted EPS guidance of $14.25 to $14.60. The company also announced a $1 billion share repurchase plan and increased its dividend by 9.5%. However, BD expects challenges in the Chinese market, forecasting a mid-single-digit decline due to value-based procurement pressures.
Despite these challenges, BD remains optimistic about the continued growth of key products and the integration of the Advanced Patient Monitoring business. The company is also focusing on R&D investment for the integration of APM, with funding allocated for fiscal year 2025. These are some of the recent developments in the company's strategic approach to growth and capital allocation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.